Back to Feed
ClinicalTrials.gov|Clinical Trial
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Medical University of South Carolina
Abstract
This is a single-center, nonrandomized, open-label dose-escalation study followed by dose-expansion of CD19- CD34t metabolically programmed CAR T-cell therapy in adult patients with relapsed or refractory CD19 B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Phase: PHASE1, PHASE2 Status: RECRUITING Conditions: B-cell Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia Interventions: Cyclophosphamide injection; Fludarabine Injection; CD19-CD34t metabolically programmed CAR transduced T-cells
Keywords
B-cell Non Hodgkin LymphomaChronic Lymphocytic Leukemia